PURITY SPECIFICATIONS, STORAGE, AND DISTRIBUTION FOR MEDICATIONS DEVELOPMENT 
(RFP NO. N01DA-2-8821)

Release Date:  December 13, 2001

NOTICE:  NOT-DA-02-021

National Institute on Drug Abuse

The National Institute on Drug Abuse (NIDA) is soliciting proposals 
from qualified organizations having the capability to act as a 
centralized repository for compounds from domestic and international 
investigators, commercial sources, and pharmaceutical companies.  The 
contract will involve the receipt, purchase, storage and analysis of 
compounds from various sources, and the shipment of these compounds to 
domestic and international test sites, as well as maintenance of an 
extensive inventory and tracking system. The major goal of this project 
is to provide NIDA with a holding site which has the capability to 
inventory, analyze and store compounds, prepared under both GMP (Good 
Manufacturing Practices) and non-GMP conditions, in amounts ranging 
from milligram quantities to several kilograms.  As some of the 
compounds may be scheduled under the Controlled Substances Act, 
demonstration of proper DEA registration and adequate security is 
mandatory.  In order to handle substances under the Controlled 
Substances Act of 1970, it is mandatory that offerors possess a DEA 
Research Registration for Schedules II to V and demonstrate the 
capability to obtain a DEA registration for Schedule I controlled 
substances.

It is anticipated that one cost reimbursement, completion type contract 
will be awarded for a period of five years with options for additional 
quantities of work each year.  RFP No. N01DA-2-8821 will be available 
electronically on or about November 15, 2001, and may be accessed 
through the FedBizOpps (URL:  http://www.fedbizopps.gov) or through the 
NIDA website at the following address: (URL: 
http://www.nida.nih.gov/RFP/RFPList.html).  Please note that the RFP 
for this acquisition will be streamlined to include only the Work 
Statement, Deliverables, Reporting Requirements, Special Requirements, 
Mandatory Qualifications, Technical Evaluation Criteria, and other 
necessary Proposal Preparation Instructions.  However, all information 
required for the submission of an offer will be contained in or 
accessible through the electronic RFP package.  Response to the RFP 
will be due on or about January 3, 2002.  This advertisement does not 
commit the Government to award a contract.

Point of Contact:

David T. Lisle, Contracts Specialist
Contracts Management Branch, OPRM
National Institute on Drug Abuse, NIH
6001 Executive Boulevard
Room 3105, MSC 9543
Bethesda, MD  20892-9543
E-mail Address:  [email protected]
Telephone:  (301) 443-6677
Fax:  (301) 443-7595
	

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

			Department of Health and Human Services (HHS)
NIH... Turning Discovery Into Health®